Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter

ConditionAdenocarcinoma of Lung

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorTang-Du Hospital

About this trial

The core purpose of this study is to investigate whether the extracellular volume (ECV) fraction measured in delay phase by dual energy computed tomography (DECT) can distinguish precancerous lesions from early-stage lung adenocarcinomas, which could assist clinical decision making for surgery operation indication and strategy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients older than 18 years old with pulmonary nodules (diameter≤3 cm).

pathologically confirmed as lung adenocarcinoma.

without history of other malignancies.

accurate hematocrit within 1 week before contrast enhanced dual energy CT examination.

Disqualifiers

with a history of allergy to iodine contrast agents and other reasons who are unable to complete the examination.

without histopathology of invasion stage, such as AAH, AIS, MIA and IAC.

history of chemotherapy, radiotherapy, or other anti-tumor therapy before contrast enhanced dual energy CT.

poor image quality.

Trial population

Patients with pulmonary nodules who intend to have contrast enhanced CT in Tangdu hospital.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

2,000 Participants

are grouped into 2 trial groups

Group A: Patients with preinvasive lung adenocarcinomas

Group B: Patients with invasive lung adenocarcinomas

Trial outcomes

Primary outcomes

Acquire DECT parameters in patients with pulmonary nodules.

Including iodine concentration (IC) in delay phase, normalized IC (NIC), effective atomic number (Zeff), and CT attenuation values of nodules from virtual monochromatic images (VMIs) (energy range from 40 to 150 keV, 10keV as interval).

Time frame

2 years

Other outcomes

Acquire relative radiological features.

Including consolidation tumor ratio (CTR), nodule's maximum diameter, spiculation, lobulation, fibrosis, distortion or cut-off of vessels and bronchi.

Time frame

2 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tang-Du Hospital

Lead sponsor

Source ClinicalTrials.gov

Apply now